AirNexis Therapeutics is focused on creating new treatments for pulmonary diseases, with an initial emphasis on chronic obstructive pulmonary disease. Its lead asset, AN01, is a dual PDE3/4 inhibitor that simultaneously drives bronchodilation and dampens inflammatory pathways, offering a synergistic mechanism of action for COPD patients. The molecule, currently in Phase 2 development, was recently in-licensed from Haisco Pharmaceutical Group, giving AirNexis worldwide rights outside China. Led by CEO Maria Fardis, the company plans to advance AN01 through global clinical trials and pursue additional indications within pulmonary medicine. The $200 million Series A financing provides the capital required to accelerate clinical development, expand regulatory activities, and build out manufacturing capabilities. No commercial revenue has yet been reported, reflecting the company’s clinical-stage status, and financial resources now largely consist of the new equity infusion.

Total raised

$200M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2026